Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
-
MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
-
MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...
-
MALVERN, Pa., March 04, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that, as part of its...
-
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S. Commercial Launch Planned to Commence in Late April or Early May 2020 Management to Host...
-
FDA Grants Appeal for IV Meloxicam New Drug Application PDUFA Goal Date of February 20, 2020 MALVERN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical...
-
MALVERN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food...
-
MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other...